Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia

被引:6
|
作者
Moradi, Arman [1 ]
Maleki, Majid [2 ]
Ghaemmaghami, Zahra [2 ]
Khajali, Zahra [2 ]
Noohi, Feridoun [2 ]
Moghadam, Maryam Hosseini [2 ]
Kalyinia, Samira [2 ]
Mowla, Seyed Javad [1 ]
Seidah, Nabil G. [3 ]
Malakootian, Mahshid [2 ]
机构
[1] Tarbiat Modares Univ, Fac Biol Sci, Dept Mol Genet, Tehran, Iran
[2] Iran Univ Med Sci, Cardiogenet Res Ctr, Rajaie Cardiovasc Med & Res Ctr, Tehran, Iran
[3] Univ Montreal, Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ, Canada
基金
美国国家科学基金会;
关键词
pre-mature CAD; Familial Hypercholesterolemia; loss-of-function; LDLR; PCSK9 (proprotein convertase subtilisin kexin type 9); RECEPTOR GENE; LIPOPROTEIN; BINDING; CLINICIAN; GUIDANCE; DATABASE; DOMAIN; RISK; FH;
D O I
10.3389/fgene.2021.625959
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Familial hypercholesterolemia (FH) is a common, yet underdiagnosed, genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol levels, which can increase the risk of early-onset coronary artery disease (CAD). In the present study, we screened the nucleotide variations of the LDLR and PCSK9 genes, as well as a part of the APOB gene, in Iranian patients with FH and premature CAD to find the genetic cause of the disorder. Fifteen unrelated individuals with a clinical diagnosis of FH and premature CAD were recruited. Direct DNA sequencing was applied to screen the whole coding exons and exon-intron boundaries of the LDLR and PCSK9 genes and the main parts of their introns, together with exon 26 of the APOB gene. The pathogenicity of the identified mutations was investigated via either segregation analyses in the family or in silico predictive software. Six different point mutations (p.Cys148Tyr, p.Cys216Tyr, p.Cys302Trp, p.Cys338Trp, p.Leu479Gln, and p.G593Afs*72) in LDLR and a double mutation (p.Asp172His and p.Ala53Val) in both LDLR and PCSK9 genes were identified in seven families with clinically diagnosed FH (43%), whereas no pathogenic mutations were found in eight families with clinically diagnosed FH. This study is the first to identify 1 pathogenic mutation in the LDLR gene (c.1014C > G [p.Cys338Trp]) and to cosegregate it from the affected individual in the family. No mutations were found in the APOB gene, whereas several silent mutations/polymorphisms were identified in the LDLR and PCSK9 genes. Genetic testing and reports on nucleotide alterations in the Iranian population are still limited. Our findings not only further confirm the significant role of FH in the incidence of premature CAD but also enlarge the spectrum of LDLR and PCSK9 variations and exhibit the heterogeneity of FH in Iranians. In patients with no mutation in the examined genes, the disease could be begotten either by a polygenic cause or by gene defects occurring in other related genes and regions not targeted in this study.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction
    Jing Gao
    Ya-Nan Yang
    Zhuang Cui
    Si-Yuan Feng
    Jing Ma
    Chang-Ping Li
    Yin Liu
    Lipids in Health and Disease, 20
  • [32] NO ASSOCIATION BETWEEN CHANGES IN LIPID PARAMETERS AND TOTAL PCSK9 IN CORONARY ARTERY DISEASE PATIENTS TREATED WITH PCSK9 INHIBITORS
    Ugovsek, S.
    Likozar, A. Rehberger
    Sebestjen, M.
    ATHEROSCLEROSIS, 2023, 379 : S173 - S173
  • [33] Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction
    Gao, Jing
    Yang, Ya-Nan
    Cui, Zhuang
    Feng, Si-Yuan
    Ma, Jing
    Li, Chang-Ping
    Liu, Yin
    LIPIDS IN HEALTH AND DISEASE, 2021, 20 (01)
  • [34] PCSK9 GENETIC VARIANTS IN PATIENTS WITH CORONARY ARTERY DISEASE - A PILOT STUDY
    Ashavaid, T. F.
    Bane, A.
    Ponde, C. K.
    Rajani, R. M.
    Pillai, S.
    ATHEROSCLEROSIS, 2018, 275 : E224 - E225
  • [35] Effect of PCSK9 inhibition on platelet reactivity in coronary artery disease patients
    Galli, Lukas
    Ondracek, Anna
    Seidl, Veronika
    Hofbauer, Thomas
    Zedan, Yasmin
    Schrutka, Lore
    Krychtiuk, Konstantin
    Lang, Irene M.
    Speidl, Walter
    Distelmaier, Klaus
    WIENER KLINISCHE WOCHENSCHRIFT, 2019, 131 : 372 - 373
  • [36] INHIBITION OF PCSK9 AFFECTS SERUM LIPOPROTEIN FUNCTIONS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
    Palumbo, M.
    Adorni, M. P.
    Zimetti, F.
    Pavanello, C.
    Giammanco, A.
    Cefalu, A. B.
    Noto, D.
    Piro, S.
    Di Pino, A.
    Averna, M.
    Calabresi, L.
    Bernini, F.
    Purrello, F.
    Scicali, R.
    ATHEROSCLEROSIS, 2022, 355 : E157 - E157
  • [37] Familial Hypercholesterolemia, Familial Combined Hyperlipidemia, and Elevated Lipoprotein(a) in Patients With Premature Coronary Artery Disease
    Vikulova, Diana N.
    Trinder, Mark
    Mancini, G. B. John
    Pimstone, Simon N.
    Brunham, Liam R.
    CANADIAN JOURNAL OF CARDIOLOGY, 2021, 37 (11) : 1733 - 1742
  • [38] ANALYSIS OF THE LDLR, APOB, PCSK9 AND LDLRAP1 GENES VARIABILITY IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA IN WEST SIBERIA USING TARGETED HIGH THROUGHPUT RESEQUENCING
    Shakhtshneider, E.
    Ivanoshchuk, D.
    Orlov, P.
    Timoshchenko, O.
    Voevoda, M.
    ATHEROSCLEROSIS, 2019, 287 : E285 - E285
  • [39] SCREENING FOR PCSK9 MUTATIONS IN SPANISH PATIENTS WITH AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA UNRELATED TO LDLR OR APOB
    Garcia-Otin, L.
    Strunk, M.
    Pueyo, M.
    Solanas, M.
    Fiddyment, S.
    Aceves, M.
    Tejedor, D.
    Pocovi, M.
    Civeira, F.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [40] PCSK9-"missing link" in familial hypercholesterolemia. New therapeutic options in hypercholesterolemia and coronary artery disease
    Thiery, J.
    Burkhardt, R.
    HERZ, 2016, 41 (04) : 281 - 289